MaaT Pharma SA (MAAT.PA)
EUR 8.1
(1.0%)
EUR 8.1
(1.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 5.42 Million EUR | -35.22% |
| 2022 | 8.37 Million EUR | 83.99% |
| 2021 | 4.55 Million EUR | -12.71% |
| 2020 | 5.21 Million EUR | -47.41% |
| 2019 | 9.91 Million EUR | 355.91% |
| 2018 | 2.17 Million EUR | 26.21% |
| 2017 | 1.72 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 4.41 Million EUR | 0.0% |
| 2024 Q1 | 4.41 Million EUR | -18.65% |
| 2023 FY | 5.42 Million EUR | -35.22% |
| 2023 Q1 | 6.93 Million EUR | -17.25% |
| 2023 Q4 | 5.42 Million EUR | -48.92% |
| 2023 Q3 | 10.62 Million EUR | 53.25% |
| 2023 Q2 | 6.93 Million EUR | 0.0% |
| 2022 Q4 | 8.37 Million EUR | 0.0% |
| 2022 Q3 | 8.37 Million EUR | 43.11% |
| 2022 Q2 | 5.85 Million EUR | 0.0% |
| 2022 Q1 | 5.85 Million EUR | 28.56% |
| 2022 FY | 8.37 Million EUR | 83.99% |
| 2021 Q1 | 4.91 Million EUR | -5.7% |
| 2021 FY | 4.55 Million EUR | -12.71% |
| 2021 Q4 | 4.55 Million EUR | 0.0% |
| 2021 Q3 | 4.55 Million EUR | -7.44% |
| 2021 Q2 | 4.91 Million EUR | 0.0% |
| 2020 Q4 | 5.21 Million EUR | 0.0% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 Q3 | 5.21 Million EUR | 0.0% |
| 2020 FY | 5.21 Million EUR | -47.41% |
| 2019 FY | 9.91 Million EUR | 355.91% |
| 2018 FY | 2.17 Million EUR | 26.21% |
| 2017 FY | 1.72 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -392.734% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 87.863% |
| Adocia SA | 4.54 Million EUR | -19.493% |
| Aelis Farma SA | 2.04 Million EUR | -164.893% |
| Biophytis S.A. | 3.11 Million EUR | -74.381% |
| Advicenne S.A. | 15.89 Million EUR | 65.872% |
| genOway Société anonyme | 5.51 Million EUR | 1.709% |
| IntegraGen SA | 642.28 Thousand EUR | -744.647% |
| Medesis Pharma S.A. | 1.2 Million EUR | -352.083% |
| Neovacs S.A. | 650 Thousand EUR | -734.615% |
| NFL Biosciences SA | 39.2 Thousand EUR | -13738.227% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -24.526% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -176.739% |
| Sensorion SA | 1.24 Million EUR | -337.179% |
| Theranexus Société Anonyme | 2.46 Million EUR | -120.464% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | -39.174% |
| TheraVet SA | 1 Million EUR | -442.175% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | 21.445% |
| argenx SE | 15.35 Million EUR | 64.667% |
| BioSenic S.A. | 15.57 Million EUR | 65.164% |
| Celyad Oncology SA | 902 Thousand EUR | -501.441% |
| DBV Technologies S.A. | 4.52 Million USD | -19.863% |
| Galapagos NV | 4.94 Million EUR | -9.729% |
| Genfit S.A. | 62.25 Million EUR | 91.286% |
| GeNeuro SA | 6.49 Million EUR | 16.439% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -1477.035% |
| Innate Pharma S.A. | 30.6 Million EUR | 82.275% |
| Inventiva S.A. | 25.61 Million EUR | 78.822% |
| MedinCell S.A. | 52.8 Million EUR | 89.725% |
| Nanobiotix S.A. | 41.66 Million EUR | 86.978% |
| Onward Medical N.V. | 16.3 Million EUR | 66.73% |
| Oryzon Genomics S.A. | 3.45 Million EUR | -57.218% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | 84.722% |
| Oxurion NV | 117 Thousand EUR | -4536.752% |
| Pharming Group N.V. | 123.65 Million EUR | 95.613% |
| Poxel S.A. | 40.14 Million EUR | 86.486% |
| GenSight Biologics S.A. | 1.04 Million EUR | -417.653% |
| Transgene SA | 17 Thousand EUR | -31811.765% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 99.812% |
| Valneva SE | 132.76 Million EUR | 95.914% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |